Skip to main content
OpenTrials
Completed

NCT Number: NCT01204372

Trial Evaluating Combined Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma

GATE 1 is an open-label, non-comparative, multicentric study evaluating the efficacy and tolerance of the combined use of Gemcitabine, Trastuzumab and Erlotinib as a first-line chemotherapy in metastatic pancreatic cancer patients.

The patients will be treated intravenously with Gemcitabine at a dose of 1000 mg/m2 for 30 min. For the first eight weeks, Gemcitabine will be administered once weekly for 7 weeks followed by one week of rest. Subsequently, Gemcitabine will be administered once weekly for three weeks followed by one week of rest.

Trastuzumab will be administered once a week at a dose of 4 mg/kg over 90 min. at D1 and then at 2 mg/kg over 30 min. for the subsequent infusions.

Erlotinib will be administered orally at a dose of 100 mg/day from C1D1.

The patients will be subjected to research for the EGFR, HER2 and KRAS status.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Metastatic Pancreatic Adenocarcinoma

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Centre Val d'Aurelle

Montpellier, 34298, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Metastatic pancreatic adenocarcinoma confirmed by histology
  • Tumor sample available
  • Measurable lesion according to RECIST criteria
  • Performance status ≥ 1
  • Life expectancy > 3 months
  • Hematology: Hb ≥ 9g/dL, neutrophils ≥ 1,500/mm3, platelets ≥ 100,000/mm3
  • Renal function: creatinine ≤ 1.5 x ULN
  • Hepatic function: total bilirubin ≤ 2.5 x ULN, transaminases ≤ 5 x ULN
  • Left ventricular ejection fraction (LVEF) ≥ 50%
  • At least a 6-month delay between the end of any previous gemcitabine-based chemotherapy and diagnosis of metastases
  • Social security
  • Informed consent obtained prior to inclusion.

Exclusion criteria

  • Non metastatic advanced local disease
  • Presence of cerebral metastases or symptomatic leptomeningeal carcinomatosis
  • Others cancers except BBC and cervical cancer receiving curative treatment
  • No previous treatment by Erlotinib or Trastuzumab
  • Known severe hypersensitivity to Erlotinib, Trastuzumab, murine proteins or Gemcitabine
  • Presence of significant co-morbidities
  • Concomitant treatment with other experimental products or other anticancer therapies
  • Breastfeeding or pregnant female, or patient of reproductive age not using adequate contraception
  • Legal incapacity or limited legal incapacity

Treatment and study plan

Gemcitabine - Trastuzumab - Erlotinib

Drug

Treatment will be administered until disease progression, patient's refusal, unacceptable toxicity or investigator's decision.

  • Gemcitabine: IV 1000 mg/m2 on D1, D8, D15, D22, D29, D36 and D43 followed by one week of rest. Subsequently on D1, D8 and D15 followed by one week of rest.
  • Trastuzumab: IV once a week; 4 mg/kg over 90 min. at D1, and 2 mg/kg over 30 min. for the subsequent infusions.
  • Erlotinib: oral route 100 mg/day from C1D1.

Primary outcomes

  1. Disease control rate according to RECIST criteria of the Gemcitabine, Trastuzumab and Erlotinib combination.

    Time frame: Every 8 weeks and at the treatment completion

    The tumor evaluation will be based on:

    • Clinical examination
    • TAP CT-scan or MRI
    • Tumor marker dosage (CEA and CA 19-9)

Secondary outcomes

  1. Progression free survival

    Time frame: Every 8 weeks and at the treatment completion

    The tumor evaluation will be based on:

    • Clinical examination
    • TAP CT-scan or MRI
    • Tumor marker dosage

  2. Overall survival

    Time frame: Every 8 weeks and at treatment completion

Sponsors and collaborators

Lead sponsor

Institut du Cancer de Montpellier - Val d'Aurelle

Other

Registry information

Official study title

Phase II Trial Evaluating the Combination of Gemcitabine, Trastuzumab and Erlotinib as First-line Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma

Acronym: GATE 1

Important dates

Study start
2010
Primary completion
2012
Study completion
2016
First posted
Sep 17, 2010
Registry last updated
Mar 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.